"Considering Optune®" Patient Education Program

"Considering Optune" is a program in which Novocure® representatives can provide education to patients with newly diagnosed or recurrent glioblastoma (GBM) who are considering Optune as a treatment option.

What does the Novocure representative do during the program?

- Answer questions about Optune
- Discuss educational and support resources that Novocure provides
- Discuss the process of initiating Optune

Craig is an Optune user and Patient Ambassador.

How does the program take place?

The Novocure representative, the patient, the patient's caregiver, and often the certified Healthcare Professional (HCP) attend the program either in person or virtually.

- In-person meetings take place in a private area where social distancing guidelines will be adhered to

OR

- Virtual meetings take place over the phone or on video call platforms such as FaceTime® or Zoom

Novocure representatives are Novocure employees and are not acting as Healthcare Professionals. They are trained to serve only as supplementary Optune educators.

How does an HCP schedule a "Considering Optune" program for a patient?

HCP

1 The HCP will identify a prospective patient with GBM who is interested in the educational session

2 The HCP will contact the Novocure representative, request a 1:1 educational program, and provide the patient's phone number for scheduling purposes

NOVOCURE REPRESENTATIVE

3 The Novocure representative will obtain the patient's signed consent form either from the HCP or directly from the patient

4 The Novocure representative will call the patient to schedule the educational session

5 The Novocure representative will conduct the training session either in person or virtually with the patient, the patient's caregiver, and often the HCP

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device.

Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions at Optune.com/IFU.

novocure®

Patient image reflects the health status of the patient at the time the photo was taken.

US-OPT-04007v2.0 Released April 2021

OPTUNE®
Elevate Expectations